drug · oligonucleotide
olpasiran
Phase 3updated 5mo agoby $AMGN AMGEN INC🔗 ChEMBL
Phase 3community read0 votes
Oligonucleotide drug with a maximum clinical stage of Phase 3 (across all indications), with 4 investigational indications.
targets
LPA mRNA
all catalysts(0)
nothing on the calendar yet
Trials studying olpasiran
- phase3OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
- phase3Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial
- phase2Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study
- phase3Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
- phase1A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment
- phase1A Study to Assess the Effect of Olpasiran on QT/QTc Intervals in Healthy Participants
- phase1A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Various Degrees of Hepatic Impairment
- —Olpasiran Expanded Access Program
News(5)
- Novartis drags peers down with triple asset failureNovartis’ shares fell 13% this week after the report of three separate late-stage asset failures. The impact went beyond the Swiss drugmaker, dragging peers down across the market.biospace · 22d ago
- Novartis drags peers down with triple asset stumbleNovartis’ shares fell 13% this week after the report of three separate late-stage asset setbacks. The impact went beyond the Swiss drugmaker, dragging peers down across the market.biospace · 22d ago
- Novartis’ cholesterol-lowering medicine fails Phase 3, clouding Lp(a) horizonsThe failure of Novartis’ pelacarsen to translate its Lp(a)-lowering effects to clinical benefits “marks a meaningful setback” for other companies taking a similar approach to cardiovascular risk, a…biospace · 25d ago
- Novartis Lp(a) drug fails to lower cardiovascular risk in closely watched ph. 3 trialNovartis’ Ionis-partnered drug designed to lower levels of Lp(a), a known cardiovascular risk factor, failed to reduce patients’ risk of a heart attack, stroke, or other major cardiovascular event…fiercebiotech · 29d ago
- Amgen’s MariTide stands alone after obesity cull while analysts seek more M&AAmgen has discontinued Phase 1 obesity candidate AMG 513, leaving MariTide as its sole weight loss asset. Meanwhile, executives said the company’s late-stage pipeline is largely full and future bus…biospace · 1mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that